Teva Loses Exclusivity On Generic Pravachol; Earlier Court Case Was Trigger

Teva has nine months to resolve questions surrounding its first-to-file rights for generic pravastatin before the expiration of Bristol-Myers Squibb's exclusivity for Pravachol in April 2006